NCT00251186

First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients

Phase II Study of First-Line Capecitabine and Cetuximab for Treatment of Metastatic Colorectal Cancer in Elderly Patients and/or Those With Multiple Comorbidities Unable to Receive Chemotherapy Doublets

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (planned)
• Sponsor: University of Medicine and Dentistry of New Jersey · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase II clinical trial measuring the effectiveness of the combination of Capecitabine and cetuximab for first line treatment of colorectal cancer in elderly patients and/or those with multiple comorbidities unable to receive standard chemotherapy. This study will be open approximately 2-3 years. Approximately 36 patients will be enrolled on this study. The study will begin enrolling at The Cancer Institute of New Jersey, with 17 patients in the first group. If more than 4 responses are noted, the accrual will continue to 36 patients throughout CINJOG.

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Capecitabine and Cetuximab

Timeline

• Start date: 2006-04-01
• Primary completion: 2006-04-01
• Completion: 2006-04-01
• First posted: 2005-11-09
• Last updated: 2010-01-26

Locations

1 site across 1 country: United States